S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Aurora Cannabis Stock Competitors

$5.95
-0.20 (-3.25 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.92
$6.10
50-Day Range
$5.95
$7.52
52-Week Range
$3.71
$18.98
Volume5.32 million shs
Average Volume4.67 million shs
Market Capitalization$1.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.17

Aurora Cannabis (NYSE:ACB) Vs. CRON, USNA, SNDL, CDXC, HEXO, and MDWD

Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Cronos Group (CRON), USANA Health Sciences (USNA), Sundial Growers (SNDL), ChromaDex (CDXC), HEXO (HEXO), and MediWound (MDWD). These companies are all part of the "medicinals & botanicals" industry.

Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Risk and Volatility

Aurora Cannabis has a beta of 3.17, indicating that its share price is 217% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Aurora Cannabis and Cronos Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis74001.36
Cronos Group32101.67

Aurora Cannabis presently has a consensus price target of $6.78, indicating a potential upside of 13.95%. Cronos Group has a consensus price target of $8.70, indicating a potential upside of 52.63%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Aurora Cannabis.

Valuation & Earnings

This table compares Aurora Cannabis and Cronos Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million5.67$-2,468,190,000.00($2.86)-2.08
Cronos Group$46.72 million45.54$-73,140,000.00($0.38)-15.00

Cronos Group has lower revenue, but higher earnings than Aurora Cannabis. Cronos Group is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aurora Cannabis and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-895.36%-11.19%-8.64%
Cronos Group-258.59%-9.48%-8.36%

Insider and Institutional Ownership

17.2% of Aurora Cannabis shares are held by institutional investors. Comparatively, 13.9% of Cronos Group shares are held by institutional investors. 5.5% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cronos Group beats Aurora Cannabis on 10 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Aurora Cannabis (NYSE:ACB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

USANA Health Sciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.17, suggesting that its stock price is 217% more volatile than the S&P 500.

Insider and Institutional Ownership

54.8% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 17.2% of Aurora Cannabis shares are owned by institutional investors. 0.2% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for USANA Health Sciences and Aurora Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00103.00
Aurora Cannabis74001.36

USANA Health Sciences currently has a consensus price target of $126.00, indicating a potential upside of 40.11%. Aurora Cannabis has a consensus price target of $6.78, indicating a potential upside of 13.95%. Given USANA Health Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe USANA Health Sciences is more favorable than Aurora Cannabis.

Earnings & Valuation

This table compares USANA Health Sciences and Aurora Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.13 billion1.59$124.66 million$5.8615.35
Aurora Cannabis$207.89 million5.67$-2,468,190,000.00($2.86)-2.08

USANA Health Sciences has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares USANA Health Sciences and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences11.09%33.65%23.22%
Aurora Cannabis-895.36%-11.19%-8.64%

Summary

USANA Health Sciences beats Aurora Cannabis on 12 of the 14 factors compared between the two stocks.

Sundial Growers (NASDAQ:SNDL) and Aurora Cannabis (NYSE:ACB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

Sundial Growers has a beta of 6.18, suggesting that its share price is 518% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.17, suggesting that its share price is 217% more volatile than the S&P 500.

Insider & Institutional Ownership

9.2% of Sundial Growers shares are owned by institutional investors. Comparatively, 17.2% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Sundial Growers and Aurora Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sundial Growers14001.80
Aurora Cannabis74001.36

Sundial Growers currently has a consensus target price of $0.7333, indicating a potential upside of 8.96%. Aurora Cannabis has a consensus target price of $6.78, indicating a potential upside of 13.95%. Given Aurora Cannabis' higher probable upside, analysts clearly believe Aurora Cannabis is more favorable than Sundial Growers.

Valuation & Earnings

This table compares Sundial Growers and Aurora Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sundial Growers$45.48 million24.57$-178,920,000.00($0.26)-2.59
Aurora Cannabis$207.89 million5.67$-2,468,190,000.00($2.86)-2.08

Sundial Growers has higher earnings, but lower revenue than Aurora Cannabis. Sundial Growers is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sundial Growers and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sundial Growers-707.37%-23.14%-20.54%
Aurora Cannabis-895.36%-11.19%-8.64%

ChromaDex (NASDAQ:CDXC) and Aurora Cannabis (NYSE:ACB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

ChromaDex has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.17, suggesting that its share price is 217% more volatile than the S&P 500.

Insider & Institutional Ownership

29.8% of ChromaDex shares are owned by institutional investors. Comparatively, 17.2% of Aurora Cannabis shares are owned by institutional investors. 11.8% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for ChromaDex and Aurora Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChromaDex00303.00
Aurora Cannabis74001.36

ChromaDex currently has a consensus target price of $13.00, indicating a potential upside of 101.55%. Aurora Cannabis has a consensus target price of $6.78, indicating a potential upside of 13.95%. Given ChromaDex's stronger consensus rating and higher probable upside, analysts clearly believe ChromaDex is more favorable than Aurora Cannabis.

Valuation & Earnings

This table compares ChromaDex and Aurora Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChromaDex$59.26 million7.42$-19,920,000.00($0.33)-19.55
Aurora Cannabis$207.89 million5.67$-2,468,190,000.00($2.86)-2.08

ChromaDex has higher earnings, but lower revenue than Aurora Cannabis. ChromaDex is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ChromaDex and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChromaDex-37.51%-76.33%-44.17%
Aurora Cannabis-895.36%-11.19%-8.64%

Summary

ChromaDex beats Aurora Cannabis on 9 of the 14 factors compared between the two stocks.

HEXO (NYSE:HEXO) and Aurora Cannabis (NYSE:ACB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Risk and Volatility

HEXO has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.17, suggesting that its stock price is 217% more volatile than the S&P 500.

Valuation and Earnings

This table compares HEXO and Aurora Cannabis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXO$60.46 million4.82$-406,370,000.00($0.96)-1.99
Aurora Cannabis$207.89 million5.67$-2,468,190,000.00($2.86)-2.08

HEXO has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for HEXO and Aurora Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HEXO22302.14
Aurora Cannabis74001.36

HEXO presently has a consensus target price of $6.6917, indicating a potential upside of 250.35%. Aurora Cannabis has a consensus target price of $6.78, indicating a potential upside of 13.95%. Given HEXO's stronger consensus rating and higher probable upside, equities research analysts plainly believe HEXO is more favorable than Aurora Cannabis.

Profitability

This table compares HEXO and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HEXO-189.28%-12.50%-9.96%
Aurora Cannabis-895.36%-11.19%-8.64%

Insider and Institutional Ownership

23.3% of HEXO shares are owned by institutional investors. Comparatively, 17.2% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

HEXO beats Aurora Cannabis on 7 of the 13 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Volatility & Risk

Aurora Cannabis has a beta of 3.17, meaning that its stock price is 217% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.

Valuation & Earnings

This table compares Aurora Cannabis and MediWound's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million5.67$-2,468,190,000.00($2.86)-2.08
MediWound$21.76 million4.37$-9,200,000.00($0.34)-10.26

MediWound has lower revenue, but higher earnings than Aurora Cannabis. MediWound is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Aurora Cannabis and MediWound, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis74001.36
MediWound00303.00

Aurora Cannabis presently has a consensus price target of $6.78, indicating a potential upside of 13.95%. MediWound has a consensus price target of $7.50, indicating a potential upside of 114.90%. Given MediWound's stronger consensus rating and higher possible upside, analysts plainly believe MediWound is more favorable than Aurora Cannabis.

Profitability

This table compares Aurora Cannabis and MediWound's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-895.36%-11.19%-8.64%
MediWound-38.43%-171.14%-31.94%

Insider and Institutional Ownership

17.2% of Aurora Cannabis shares are held by institutional investors. Comparatively, 14.0% of MediWound shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aurora Cannabis beats MediWound on 7 of the 13 factors compared between the two stocks.


Aurora Cannabis Competitors List

Competitor NameBTM RankShare PriceAnalysts' Price TargetMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Cronos Group logo
CRON
Cronos Group
1.5$5.70
-5.3%
$8.70
-52.6%
$2.13 billion$46.72 million-13.90665
USANA Health Sciences logo
USNA
USANA Health Sciences
2.2$89.93
-1.0%
$126.00
-40.1%
$1.80 billion$1.13 billion13.561,943Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.3$0.67
-4.5%
$0.73
-9.0%
$1.12 billion$45.48 million-1.16394Analyst Upgrade
ChromaDex logo
CDXC
ChromaDex
1.8$6.45
-3.7%
$13.00
-101.6%
$439.87 million$59.26 million-17.43110Gap Up
HEXO logo
HEXO
HEXO
1.6$1.91
-2.1%
$6.69
-250.3%
$291.71 million$60.46 million-1.26N/AAnalyst Report
MediWound logo
MDWD
MediWound
1.8$3.49
-0.9%
$7.50
-114.9%
$95.06 million$21.76 million-9.9775News Coverage
Natural Alternatives International logo
NAII
Natural Alternatives International
1.5$14.21
-0.1%
N/A$91.44 million$118.88 million9.54175News Coverage
GRVI
Grove
0.0$5.10
-0.4%
N/A$72.46 millionN/A0.0090
BON
Bon Natural Life
0.0$8.90
-7.2%
N/A$71.20 million$18.22 million0.008,787News Coverage
Gap Up
Mannatech logo
MTEX
Mannatech
1.8$36.00
-1.6%
N/A$68.15 million$151.41 million11.50226Gap Up
HAPP
Happiness Biotech Group
1.4$0.94
-4.3%
N/A$30.04 million$71.49 million31.33151News Coverage
Gap Up
This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.